{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:00:09Z","timestamp":1772121609573,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.semnephrol.2014.04.007","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T08:41:02Z","timestamp":1397810462000},"page":"323-332","source":"Crossref","is-referenced-by-count":9,"title":["Aldosterone and Volume Management in Hypertensive Heart Disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Domenic A.","family":"Sica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2014.04.007_bib1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11906-004-0069-6","article-title":"Aldosterone and aldosterone antagonism in systemic hypertension","volume":"6","author":"Frishman","year":"2004","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.HDX.0000061698.20666.aa","article-title":"Aldosterone and aldosterone antagonism in cardiovascular disease","volume":"5","author":"Stier","year":"2003","journal-title":"Heart Dis"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib3","first-page":"52","article-title":"Aldosterone antagonists in hypertension and heart failure","volume":"61","author":"Mantero","year":"2000","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/106002809002400112","article-title":"Spironolactone: a re-examination","volume":"24","author":"Skluth","year":"1990","journal-title":"DICP"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib5","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2165\/00003495-200363190-00001","article-title":"Aldosterone receptor antagonists for hypertension","volume":"63","author":"Liew","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/clpt.1986.219","article-title":"Influence of food on the bioavailability of spironolactone","volume":"40","author":"Overdiek","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/03602537808993782","article-title":"Spironolactone: disposition, metabolism, pharmacodynamics and bioavailability","volume":"8","author":"Karim","year":"1978","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","article-title":"Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites","volume":"29","author":"Gardiner","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib11","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/0016-5085(92)91730-R","article-title":"Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites","volume":"102","author":"Sungaila","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11906-004-0029-1","article-title":"Aldosterone receptor antagonism and end-stage renal disease","volume":"6","author":"McLaughlin","year":"2004","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","article-title":"The 45-year story of the development of an anti-aldosterone more specific than spironolactone","volume":"217","author":"Menard","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib15","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","article-title":"Pharmacokinetics and metabolism of [14C] eplerenone after oral administration to humans","volume":"31","author":"Cook","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib16","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1124\/dmd.30.12.1344","article-title":"Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5","volume":"30","author":"Cook","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib17","first-page":"1332","article-title":"Pharmacokinetics of eplerenone in special populations","volume":"22","author":"Tolbert","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0091270005275894","article-title":"Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment","volume":"45","author":"Ravis","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib19","first-page":"1331","article-title":"Pharmacokinetics of eplerenone coadministered with other medications","volume":"22","author":"Tolbert","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/00498250310001649341","article-title":"Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data","volume":"34","author":"Cook","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib21","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/BF01263103","article-title":"Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites","volume":"23","author":"Campra","year":"1978","journal-title":"Am J Dig Dis"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00003088-199630030-00004","article-title":"Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships","volume":"30","author":"Sica","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-8278(03)00188-0","article-title":"Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety","volume":"39","author":"Santos","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/bmj.4.5732.401","article-title":"Spironolactone diuresis in patients with cirrhosis and ascites","volume":"4","author":"Eggert","year":"1970","journal-title":"BMJ"},{"issue":"Suppl 1","key":"10.1016\/j.semnephrol.2014.04.007_bib25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00004836-198100031-00016","article-title":"Diuresis in the ascitic patient: a randomized controlled trial of thee regimens","volume":"3","author":"Fogel","year":"1981","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib26","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0016-5085(83)90198-1","article-title":"Randomized comparative study of efficacy of furosemide versus spironolactone in patients with liver cirrhosis and ascites","volume":"84","author":"Perez\u2010Ayuso","year":"1983","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib27","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/0016-5085(92)91730-R","article-title":"Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites","volume":"102","author":"Sungaila","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cpt1977212234","article-title":"Metolazone and spironolactone in cirrhosis and the nephrotic syndrome","volume":"21","author":"Lang","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib29","first-page":"15","article-title":"Comparison of six treatments of ascites in patients with liver cirrhosis","volume":"30","author":"Descos","year":"1983","journal-title":"A clinical trial. Hepatogastroenterology"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1572-0241.2000.01980.x","article-title":"Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study","volume":"95","author":"Li","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000164149","article-title":"Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry","volume":"113","author":"Peacock","year":"2009","journal-title":"Cardiology"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib32","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cardfail.2007.03.011","article-title":"High prevalence of renal dysfunction and its impact on outcome in 118.465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database","volume":"13","author":"Heywood","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure, Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejim.2013.08.711","article-title":"Mineralocorticoid receptor antagonism in acutely decompensated heart failure","volume":"25","author":"Ferreira","year":"2014","journal-title":"Eur J Int Med"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib35","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/j.ijcard.2013.11.023","article-title":"Use of natriuretic doses of spironolactone for treatment of loop diuretic resistant acute decompensated heart failure","volume":"170","author":"Eng","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000346447","article-title":"Increased spironolactone in advanced heart failure: effect of does greater than 25-mg\/day on plasma potassium concentration","volume":"3","author":"Shchekochikhin","year":"2013","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib37","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","article-title":"Resistant hypertension: comparing hemodynamic management to specialist care","volume":"39","author":"Taler","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib38","first-page":"686","article-title":"Treatment of loop-diuretic resistant edema by the addition of metolazone","volume":"22","author":"Ram","year":"1977","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib39","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0140-6736(62)92199-2","article-title":"The effects of spironolactone and chlorthalidone on arterial pressure","volume":"1","author":"Cranston","year":"1962","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jama.1968.03140220023006","article-title":"Antihypertensive actions of diuretics. Comparative study of an aldosterone antagonist and a thiazide, alone and together","volume":"204","author":"Winer","year":"1968","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1742-1241.1981.tb08299.x","article-title":"Spironolactone and hydroflumethiazide in the treatment of hypertension","volume":"35","author":"Akbar","year":"1981","journal-title":"Br J Clin Pract"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib42","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00003495-200262030-00003","article-title":"Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats","volume":"62","author":"Sica","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/01.HYP.0000203147.75714.ba","article-title":"Chlorthalidone has it always been the best thiazide-type diuretic","volume":"47","author":"Sica","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248413497257","article-title":"Diuretics: a review and update","volume":"19","author":"Roush","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib45","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","article-title":"Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study","volume":"30","author":"Bobrie","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","article-title":"How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone is patients with congestive heart failure","volume":"10","author":"Svensson","year":"2004","journal-title":"J Card Fail"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2012.352","article-title":"Spironolactone prevent chronic kidney disease caused by ischemic acute injury","volume":"83","author":"Barrera-Chimal","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib48","doi-asserted-by":"crossref","unstructured":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(Suppl 1):S1-290.","DOI":"10.1053\/j.ajkd.2004.03.003"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11897-005-0011-5","article-title":"The risks and benefits of aldosterone antagonists","volume":"2","author":"Sica","year":"2005","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib50","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/ndt\/gft281","article-title":"Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial","volume":"28","author":"Esteghamati","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib51","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-99-3-405","article-title":"Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention","volume":"99","author":"Oster","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib52","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1524-6175.2002.01510.x","article-title":"Eplerenone: a new aldosterone receptor antagonist: are the FDA\u2019s restrictions appropriate","volume":"4","author":"Sica","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","article-title":"The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease","volume":"73","author":"Edwards","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib54","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11906-013-0414-8","article-title":"Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles","volume":"16","author":"Danjuma","year":"2014","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib55","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/HJH.0000000000000047","article-title":"Effect of intensified diuretic therapy on overnight rostral fluid shift and obstructive sleep apnea in patients with uncontrolled hypertension","volume":"32","author":"Kasai","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib56","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ki.1994.298","article-title":"Co-administration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure","volume":"46","author":"Fliser","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib57","first-page":"134","article-title":"Treatment of frusemide resistant oedema with metolazone","volume":"11","author":"Asscher","year":"1974","journal-title":"Clin Trials J"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib58","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00041552-200309000-00001","article-title":"Diuretic use in stage five chronic kidney disease and end-stage renal disease","volume":"12","author":"Sica","year":"2003","journal-title":"Curr Opinion Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib59","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0954-6820.1971.tb07423.x","article-title":"The supra-additive natriuretic effect addition of quinethazone or bendroflumethazide during long term treatment with furosemide and spironolactone","volume":"190","author":"Oleson","year":"1971","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib60","first-page":"883","article-title":"Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone","volume":"123","author":"Khan","year":"1980","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib61","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/pgmj.47.554.789","article-title":"Clinical experience with metolazone in fifty-two African patients: synergy with frusemide","volume":"47","author":"Gunstone","year":"1971","journal-title":"Postgrad Med J"},{"issue":"Suppl","key":"10.1016\/j.semnephrol.2014.04.007_bib62","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.0954-6820.1986.tb18120.x","article-title":"Potassium-sparing diuretics","volume":"707","author":"Dyckner","year":"1986","journal-title":"Acta Med Scand"},{"issue":"455-61","key":"10.1016\/j.semnephrol.2014.04.007_bib63","first-page":"11","article-title":"Hydrochlorothiazide versus spironolactone: long-term metabolic modifications in patients with essential hypertension","volume":"31","author":"Garc\u00e1 Puig","year":"1991","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib64","first-page":"401","article-title":"Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension","volume":"21","author":"Jansen","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib65","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib66","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib67","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib68","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1388-9842(02)00122-8","article-title":"Torasemide in chronic heart failure: results of the TORIC study","volume":"4","author":"Cosin","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib69","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0014-2999(91)90812-5","article-title":"Anti-aldosteronergic effect of torasemide","volume":"205","author":"Uchida","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib70","doi-asserted-by":"crossref","first-page":"e73737","DOI":"10.1371\/journal.pone.0073737","article-title":"The diuretic torsemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes","volume":"8","author":"Gravez","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib71","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib72","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib73","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1527-5299.2004.02814.x","article-title":"Aldosterone receptor antagonism: interface with hyperkalemia in heart failure","volume":"10","author":"Sica","year":"2004","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib75","doi-asserted-by":"crossref","first-page":"c1768","DOI":"10.1136\/bmj.c1768","article-title":"Spironolactone use and renal toxicity: population-based longitudinal analysis","volume":"340","author":"Wei","year":"2010","journal-title":"Brit Med J"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib76","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ahj.2004.10.005","article-title":"Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure","volume":"148","author":"Tamirisa","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.007_bib77","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.HYP.2.5.672","article-title":"Clinical and biochemical effects of spironolactone administered once daily in primary hypertension","volume":"2","author":"Schersten","year":"1980","journal-title":"Hypertension"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929514000497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929514000497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T20:08:02Z","timestamp":1716667682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929514000497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0270929514000497"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2014.04.007","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718490210.793497472","asserted-by":"object"}]},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}